Acute myelogenous leukemia in Down's syndrome: Report of a single pediatric institution using a BFM treatment strategy

Leukemia Research

Volumn 22, Issue 5, 1998, Pages 465-472

  Zubizarreta, Pedro ^a   Felice, María S ^a   Alfaro, Elizabeth ^a   Fraquelli, Lidia ^a   Casak, Sandra ^a   Quinteros, Rubén ^a   Cygler, Ana ^a   Gallego, Marta ^a   Pérez, Laura E ^a   Sackmann Muriel, Federico ^a  

^a HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

Author keywords

Acute myelogenous leukemia; BFM; Down's syndrome

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IDARUBICIN; MERCAPTOPURINE; PREDNISONE; TIOGUANINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DOWN SYNDROME; FEMALE; HUMAN; INFANT; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; LUNG INFECTION; MALE; MYELODYSPLASIA; MYELOFIBROSIS; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SEPSIS; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL;

ANTIGENS, CD; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARGENTINA; BONE MARROW CELLS; CHILD, PRESCHOOL; CYTARABINE; DOWN SYNDROME; ETOPOSIDE; FEMALE; HUMANS; IDARUBICIN; INFANT; KARYOTYPING; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0032078283     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(98)00016-2     Document Type: Article

References (30)

1. Zipursky A., Peeters M., Poon A. Megakaryoblastic leukemia and Down's syndrome: a review. Pediatr Hematol Oncol. 4:1987;11.
2. Homans A.C., Verissimo A., Vlacha V. Transient abnormal myelopoiesis of infancy associated with trisomy 21. Am J Pediatr Hematol Oncol. 15:1993;392.
3. Zubizarreta P., Sackmann-Muriel F., Fernández Barbieri M.A. Transient myeloproliferative disorder associated with trisomy 21, a wide range syndrome: report of two cases with trisomy 21 mosaicism. Med Pediatr Oncol. 25:1995;60.
4. Hayashi Y., Egushi M., Sugita K.et al. Cytogenetic findings and clinical features in acute leukemia and transient myeloproliferative disorder in Down's syndrome. Blood. 72:1988;15.
5. Wong K.Y., Jones M.M., Srivastava A.K., Gruppo R.A. Transient myeloproliferative disorder and acute nonlymphoblastic leukemia in Down's syndrome. J Pediatr. 112:1988;18.
6. Kurahashi H., Hara J., Yumura-Yagi K.et al. Monoclonal nature of transient abnormal myelopoiesis in Down's syndrome. Blood. 77:1991;1161.
7. Tchernia G., Lejeune F., Boccara J.F., Denavit M.F., Dommergues J.P., Bernaudin F. Erythroblastic and/or megakaryoblastic leukemia in Down's syndrome: treatment with low-dose arabinosyl cytosine. J Pediatr Hematol Oncol. 18:1996;59.
8. Zipursky A, Wang H, Brown EJ, Doyle JJ, Iyer R. The megakaryoblastic leukemias of Down's syndrome (DS): a difference in the in vivo and in vitro potential for differentiation of leukemic cells in transient leukemia (TL) and myelodysplasia/acute megakaryoblastic Leukemia (AMKL). Blood 1994;84:316a (Abstract 1250).
9. Zipursky A. The treatment of children with acute megakaryoblastic leukemia who have Down's syndrome. J Pediatr Hematol Oncol. 18:1996;10.
10. Doyle JI, Zipursky A. Down's syndrome children with neonatal transient leukemia: survival and risk of subsequent myelodysplasia and leukemia. Blood 1994;84:316a (Abstract 1249).
11. Sackmann-Muriel F., Zubizarreta P., Felice M.S.et al. Results of treatment with an intensive induction regimen using idarubicin combination with cytarabine and etoposide in children with acute myeloblastic leukemia. Leuk Res. 20:1996;973.
12. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457.
13. Peto R., Pike M.C., Armitage P.et al. Design and analysis of randomized clinical trials requiring prolonged observation on each patient. II Analysis and examples. Br J Cancer. 35:1977;1.
14. Tarone R.E., Wara J. On distribution-free test for equality of survival distribution. Biometrika. 64:1977;156.
15. Koike T., Aoki S., Maruyama S.et al. Cell surface phenotyping of megakaryoblasts. Blood. 69:1987;957.
16. Lie S.O., Jonmundsson G., Mellander L., Siimes M.A., Yssing M., Gustafsson G. A population-based study of 272 children with acute myeloid leukemia treated on two consecutive protocols with different intensity: best outcome in girls, infants, and children with Down's syndrome. Br J Haematol. 94:1996;82.
17. Levitt G.A., Stiller C.A., Chessells J.M. Prognosis of Down's syndrome with acute leukemia. Arch Dis Child. 65:1990;212.
18. Kojima S., Matsuyama T., Sato T.et al. Down's syndrome and acute leukemia in children: an analysis of phenotype by use of monoclonal antibodies and electron microscopic platelet peroxidase reaction. Blood. 76:1990;2348.
19. Hirt A., Luethy A.R., Mueller B., Mueller B., Gugler E., Wagner H.P. Acute megakaryoblastic leukemia in children identified by immunological marker studies. Am J Pediatr Hematol Oncol. 12:1990;27.
20. San Miguel J.F., Gonzalez M., Cañizo M.C.et al. Leukemias with megakaryoblastic involvement: clinical, hematological and immunologic characteristics. Blood. 72:1988;402.
21. Bennett J.M., Catovsky D., Daniel M.T.et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). Ann Intern Med. 103:1985;460.
22. Creutzig U., Ritter J., Vormoor J.et al. Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group. Leukemia. 10:1996;1677.
23. Lorand-Metze I., Vasallo J., Yoko Aoki R., De Souza C.A. Acute megakaryoblastic leukemia: importance of bone marrow biopsy in diagnosis. Leuk Lymphoma. 4:1991;75.
24. Groopman J.E. The pathogenesis of myelofibrosis in myeloproliferative disorders. Ann Intern Med. 92:1980;857.
25. Dördelmann M, Schrappe M, Reiter A, et al. Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Med Pediatr Oncol 1996:27:246 (Abstract O-140).
26. Ravindranath Y., Abella E., Krischer J.P.et al. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood. 80:1992;2210.
27. Kojima S., Kato K., Matsumaya T., Yoshikawa T., Horibe K. Favorable treatment outcome in children with acute myeloid leukemia and Down's syndrome. Blood. 81:1993;3164.
28. Lange BJ, Smith FO, Kobrinsky N et al. Therapy of acute myeloid Leukemia (AML) and myelodysplastic syndrome (MDS) in children with Down's syndrome (DS). Proc Am Soc Clin Oncol 1996;15:368 (Abstract 1092).
29. Garré M.L., Relling M.V., Kalwinsky D.et al. Pharmacokinetics and toxicity of methotrexate in children with Down's syndrome and acute lymphocytic leukemia. J Pediatr. 111:1987;606.
30. Arenson E.B. Jr., Forde M.D. Bone marrow transplantation for acute leukemia and Down's syndrome: report of a successful case and results of a national survey. J Pediatr. 114:1989;69.